McIlrath & Eck’s Adaptive Biotechnologies ADPT Stock Holding History

McIlrath & Eck’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-185	Closed	-$7K	–	786
2021 Q1	$7K	Hold	185	–	–	﹤0.01%	524
2020 Q4	$11K	Hold	185	–	–	﹤0.01%	396
2020 Q3	$9K	Hold	185	–	–	﹤0.01%	391
2020 Q2	$9K	Hold	185	–	–	﹤0.01%	364
2020 Q1	$5K	Hold	185	–	–	﹤0.01%	418
2019 Q4	$6K	Buy	185 +5	+3%	+$144	﹤0.01%	445
2019 Q3	$6K	Buy	+180	New	+$7.35K	﹤0.01%	423

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

McIlrath & Eck's ADPT Position: Q2 2021 in Review

McIlrath & Eck sold out of Adaptive Biotechnologies (ADPT) in Q2 2021, closing a stake of 185 shares — an estimated $7K sold.

McIlrath & Eck first reported a position in ADPT in Q3 2019 and held it in 7 quarters. The position peaked at $11K in Q4 2020. 230 funds tracked by Wall St. Rank hold ADPT as of Q2 2021.

McIlrath & Eck reported no remaining Adaptive Biotechnologies position as of Q2 2021 after selling out during the quarter.
McIlrath & Eck sold 185 Adaptive Biotechnologies shares in Q2 2021, an estimated $7K.
McIlrath & Eck first reported a position in Adaptive Biotechnologies in Q3 2019 and held it in 7 quarters.
McIlrath & Eck's Adaptive Biotechnologies position peaked at $11K in Q4 2020.
230 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2021.

Based on McIlrath & Eck's 13F filing for Q2 2021, filed 9 Aug 2021.